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Abstract
Diabetic neuropathy (DN) is one of the most frequent and troublesome complications of dia-
betes mellitus. Evidence from diabetic animal models and diabetic patients suggests that
reduced availability of neuroprotective and pro-angiogenic factors in the nerves in combina-
tion with a chronic pro-inflammatory microenvironment and high level of oxidative stress,
contribute to the pathogenesis of DN. Mesenchymal stem cells (MSCs) are of great interest
as therapeutic agents for regenerative purposes, since they can secrete a broad range of
cytoprotective and anti-inflammatory factors. Therefore, the use of the MSC secretome may
represent a promising approach for DN treatment. Recent data indicate that the paracrine
potential of MSCs could be boosted by preconditioning these cells with an environmental or
pharmacological stimulus, enhancing their therapeutic efficacy. In the present study, we
observed that the preconditioning of human adipose tissue-derived MSCs (AD-MSCs) with
150ȝM or 400ȝM of the iron chelator deferoxamine (DFX) for 48 hours, increased the abun-
dance of the hypoxia inducible factor 1 alpha (HIF-1Į) in a concentration dependent man-
ner, without affecting MSC morphology and survival. Activation of HIF-1Į led to the up-
regulation of the mRNA levels of pro-angiogenic factors like vascular endothelial growth fac-
tor alpha and angiopoietin 1. Furthermore this preconditioning increased the expression of
potent neuroprotective factors, including nerve growth factor, glial cell-derived neurotrophic
factor and neurotrophin-3, and cytokines with anti-inflammatory activity like IL4 and IL5.
Additionally, we observed that these molecules, which could also be used as therapeutics,
were also increased in the secretome of MSCs preconditioned with DFX compared to the
secretome obtained from non-preconditioned cells. Moreover, DFX preconditioning
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significantly increased the total antioxidant capacity of the MSC secretome and they showed
neuroprotective effects when evaluated in an in vitro model of DN. Altogether, our findings
suggest that DFX preconditioning of AD-MSCs improves their therapeutic potential and
should be considered as a potential strategy for the generation of new alternatives for DN
treatment.
Introduction
The incidence of diabetes mellitus (DM) is growing and reaching epidemic proportions with
more than 260 million patients worldwide [1]. The most frequent and earliest complication
associated to diabetes mellitus is diabetic neuropathy (DN), affecting 60% of type 1 and type 2
DM patients [2]. DN can affect sensory, motor or autonomic nerve fibers in any part of the
body. However, the most common form is the distal symmetry sensory-motor neuropathy,
affecting the lower extremities [3]. Patients afflicted with DN perceive a significant reduction
in quality of life, due to the loss of sensation in different areas of the body, chronic pain and
recurrent ulcerations caused by an impaired pain response, and a reduced blood flow to the
affected areas [4]. These ulcerations often develop gangrenous infections leading to the ampu-
tation of the affected limb [4]. Thus, DN is responsible for 20% of the hospitalizations of DM
patients and is the second leading cause of amputation worldwide, exceeded only by amputa-
tions caused by accidental trauma [5].
Although DN is clearly a multifactorial disease, the specific mechanisms that contribute to
DN onset and progression are not completely understood. However, the increment of reactive
oxygen species (ROS) caused by exacerbated glucose metabolism appears to be the main mech-
anism responsible for nerve fiber degeneration [6, 7]. Increased ROS levels induce: i) apoptosis
of neurons and Schwann cells with a concomitant reduction in the local levels of several neuro-
protective factors; ii) reduction in the local blood flow to nerve fibers and a decline in the
angiogenic process; and iii) a chronic pro-inflammatory microenvironment [6, 7]. Therefore,
reduced local levels of neuroprotective, pro-angiogenic and anti-inflammatory factors clearly
correlate with the onset and progression of DN [8, 9].
Despite the continued increased incidence of DM, there is no effective clinical treatment
focused on the mechanisms that lead to the development of DN. All current clinical treatments
are limited to controlling blood glucose levels and to relieving symptomatic pain [10]. There-
fore, more effective therapies are needed to improve nerve function in patients with DN.
Recently, it has been proposed that the use of stem cells could be a promising therapeutic
strategy for the management of complex diseases like DN since unlike conventional pharma-
cological treatments, stem cells may act through multiple mechanisms [11]. Among different
types of adult stem cells, mesenchymal stem cells (MSCs) have several comparative advantages
that make them a very attractive candidate for the treatment of DN. MSCs can: i) easily be iso-
lated from different tissues including bone marrow, umbilical cord blood and adipose tissue
and can be highly expanded in vitro [12]; ii) exhibit cellular plasticity, so in theory they could
differentiate into neurons and Schwann cells [13, 14]; iii) produce high levels of trophic cues
including neuroprotective and pro-angiogenic factors [15]; iv) are able to reduce high levels of
oxidative stress [16]; and v) are defined as immunomodulatory cells. Thus, by producing anti-
inflammatory molecules they could reduce chronic inflammatory processes [17]. These prop-
erties have led researchers to evaluate the role of local administration of MSCs in animal mod-
els of DM as a therapeutic option for DN treatment. It has been reported that unilateral
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intramuscular administration of MSCs in diabetic animals induces a partial recovery of
motor and sensory nerve conduction velocity, a restoration of normal structure of nerve
fibers, and an increased blood flow to damaged nerves only in the transplanted side com-
pared to the vehicle treated side [18–20]. Furthermore, authors reported an increased in the
levels of several trophic factors, including beta-fibroblast growth factor (bFGF), vascular
endothelial growth factor (VEGF), nerve growth factor (NGF), and neurotrophin-3 (NT3)
in the periphery of nerves [18–20]. These data, added to the lack of differentiation of MSCs
into neurons or Schwann cells, suggest that the therapeutic effect observed is mainly related
to the secretion of paracrine molecules by MSCs, which enables the recovery of normal lev-
els of angiogenic and neurotrophic factors [18–20].
It is well known that once in the damaged tissue, MSCs are able to sense the microenviron-
ment and change the pattern of secreted biomolecules according to the special needs of the
damaged tissue [21]. Recently, it has been reported that this response could also be achieved in
vitro by subjecting MSCs to a preconditioning stimulus, leading to the modulation of their
paracrine action [22]. The preconditioning process generally consists of incubating these cells
with a toxic agent at a sub-lethal concentration. This process leads to the up-regulation of
expression and secretion of several molecules that are needed to reduce damage. In this sense,
it has been reported that preconditioning of MSCs with hypoxia or with reactive oxygen spe-
cies (ROS) inducing agents stimulates the secretion of high levels of pro-angiogenic and anti-
apoptotic factors [23–25]. Moreover, lipopolysaccharide or interferon gamma preconditioning
induces the secretion of molecules with anti-inflammatory activity [26, 27]. Accordingly, this
kind of strategy could be used to induce the production and secretion of an appropriate com-
bination and ratio of trophic factors specific for a determined pathology, thus enhancing the
effectiveness of the therapy.
Our work aimed to evaluate whether the in vitro preconditioning of adipose tissue-derived
MSCs (AD-MSCs) with the iron chelator deferoxamine (DFX), a hypoxia mimetic agent with
antioxidant properties, was able to increase the production and secretion of pro-angiogenic,
neuroprotective, and anti-inflammatory molecules relevant for the clinical management of
DN.
Materials and methods
Isolation, expansion and characterization of AD-MSCs
Human AD-MSCs were isolated from freshly subcutaneous adipose tissue samples (abdominal
region) obtained from liposuction aspirates of four patients undergoing cosmetic liposuction
at Clı´nica Alemana, Santiago, Chile after obtaining written informed consent. Donors were
female between 22 and 56 years of age and with a body mass index (BMI) of 25 ± 1 (Mean ±
SEM). All used protocols were approved by the Ethics Committee of Facultad de Medicina
Clı´nica Alemana-Universidad del Desarrollo.
For MSC isolation, 200ml aliquots of fat were washed twice with equal volume of phos-
phate-buffered saline (PBS) and cut into small pieces. Samples were digested with 3mg/ml col-
lagenase type II (Gibco, Grand Island, NY) in PBS and incubated 30 minutes at 37˚C. At the
end of digestion, 10% fetal bovine serum (FBS) (Gibco, Auckland, NZ) was added to neutralize
collagenase. The mixture was then centrifuged at 400 g for 10 minutes to remove floating adi-
pocytes. Pellets were re-suspended in ċ-minimum essential medium (ċ-MEM) (Gibco, Auck-
land, NZ) supplemented with 10% FBS and 0.16mg/ml gentamicin (Sanderson Laboratory,
Santiago, Chile). Cells were plated at a density of 7000 cells/cm2 and cultured at 37˚C in a 5%
CO2 atmosphere. When cells reached 90% confluency, they were detached with 0.25% trypsin,
2.65mM EDTA (Sigma-Aldrich, St. Louis, MO), centrifuged and subcultured at 7000 cells/
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cm2. After two subcultures, cells were characterized according to their adipogenic and osteo-
genic differentiation potential. For this, MSCs were incubated with adipogenic differentiation
media consisting of ċ-MEM supplemented with 10% FBS, 1μMdexamethasone (Sigma-
Aldrich) and 10μM rosiglitazone (Cayman Chemicals, Ann Arbor, MI) for 15 days or osteo-
genic differentiation media composed by ċ-MEM supplemented with 10% FBS, 0.1μM dexa-
methasone, 50μg/ml ascorbate-2-phosphate (Sigma-Aldrich) and 10mM beta-glycerol
phosphate (Sigma-Aldrich) for 21 days. In both cases, medium containing differentiation sti-
muli was replaced every three days. To evaluate adipogenic potential, cultures were stained
with Oil Red-O (Sigma-Aldrich). To evaluate osteogenic potential, cultures were fixed with
10% ethanol and stained with Alizarin Red-S (Sigma-Aldrich) as previously described [21].
Immunophenotyping was performed by flow cytometry analysis after immunostaining
with monoclonal antibodies against putative human MSC markers CD29 (FITC-conjugated,
clone TS2/16), CD13 (FITC-conjugated, clone WM-15), CD105 (PE-conjugated, clone SN6),
CD73 (PE-conjugated, clone AD2), and CD90 (PE-conjugated, clone 5E10), or characteristic
markers of other cell lineages: CD235a (APC-conjugated, clone HIR2), CD31 (APC-conju-
gated, clone WM-59), and CD45 (APC-conjugated, clone 2D1) as previously described [28].
All antibodies were purchased from eBioscience (San Diego, CA).
MSC preconditioning with DFX and determination of cell viability
MSCs (passage 3) at 70% confluency were incubated for 48 hours in ċ-MEMwithout FBS and
supplemented with 150μMDFX (Sigma-Aldrich), 400μMDFX or double distilled water (vehi-
cle) as a negative control. After preconditioning, cells were trypsinized and the number of liv-
ing cells was estimated with trypan blue solution dye test. Briefly, a 1:1 dilution of trypan blue
solution (Sigma-Aldrich) with cell suspension was used. Then 10μl of the mixed suspension
was loaded into a hemocytometer, and the number of viable cells was determined under a
phase contrast microscope.
Purification of MSC secretome
After the incubation of MSCs with DFX or vehicle, the MSC secretomes were obtained by har-
vesting the culture media. The media were centrifuged at 400 g for 10 minutes to remove
whole cells, and concentrated 10 times (v/v) using 3 kDa cutoff filters (Millipore, Midlesex,
MA). In order to completely eliminate DFX from the secretome, the concentrates were washed
twice with 15ml of PBS and re-concentrated again with the same filters and frozen at -80˚C
until use.
Quantification of HIF-1Į levels
After preconditioning with DFX, MSCs were trypsinized and lysated with cell lysis buffer con-
taining protease inhibitor cocktail (Thermo, Waltham, MA). HIF-1ċ abundance was evaluated
in cell lysates using the human HIF-1ċ ELISA kit (Abcam, Cambridge, UK), following manu-
facturer‘s instructions. Data were normalized per mg of protein present in each sample using
the BCA protein assay kit (Thermo). Data were presented as fold change in preconditioned
versus non-preconditioned cells.
Quantification of mRNA levels of pro-angiogenic, neuroprotective and
anti-inflammatory factors
After preconditioning with DFX, total RNA was purified using Trizol (Invitrogen, Grand
Island, NY) following manufacture‘s instructions. Two micrograms of total RNA were used to
MSC preconditioning increases the secretion of trophic factors relevant for DN treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0178011 May 19, 2017 4 / 22
perform reverse transcription with MMLV reverse transcriptase (Invitrogen) and oligo dT
primers. Real time PCR reactions were performed in a 10μl final volume containing: 50ng
cDNA, PCR LightCycler-DNAMaster SYBERGreen reaction mix (Roche, Indianapolis, IN),
3mMMgCl2 and 0.5μM of the primers to amplify the pro-angiogenic factors VEGFċ, bFGF,
Angiopoietin-1 (ANG-1), and platelet-derived growth factor (PDGF); the neuroprotective fac-
tors NGF, NT3, glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic
factor (BDNF) and ciliary neurotrophic factor (CNTF) and the anti-inflammatory factors IL4,
IL5, IL10 and tumor necrosis factor stimulated gene 6 (TSG6) (Table 1), using a Light-Cycler
1.5 thermocycler (Roche). To ensure that amplicons were generated from mRNA and not
from genomic DNA, controls without reverse transcriptase during the reverse transcription
reaction were included. Analysis of melting curve was used to ensure that only one product
was amplified during the reaction. Agarose gel electrophoresis was used to characterize ampli-
con sizes. Relative quantifications were performed by the ïïCTmethod [21]. The mRNA level
of each target gene was normalized against the mRNA levels of the housekeeping genes elonga-
tion factor 1 alpha 1 (EEF1A1) and ribosomal protein L13A (RPL13A) of the same sample.
Data were presented as fold change of gene expression in preconditioned versus non-precondi-
tioned cells.
Quantification of protein levels of pro-angiogenic, neuroprotective and
anti-inflammatory factors
After preconditioning, VEGF-ċ, NGF, and IL4 levels were measured in the MSC secretomes
using the human VEGF-ċ ELISA kit (eBioscience); human beta-NGF ELISA kit (RayBiotech);
and human IL4 high sensitivity ELISA kit (eBioscience), respectively.
Determination of total antioxidant capacity of MSC secretomes
Total antioxidant capacity was determined in reaction volumes of 50ċl of MSC secretomes
using the Antioxidant Assay kit (Cayman Chemical) following manufacturer‘s instructions.
Results were presented as fold change in secretomes of preconditioned versus non-precondi-
tioned cells.
Table 1. Specific primers for real-time reverse transcriptase-polymerase chain reaction (RT-PCR) amplification.
Gen Primer Foward Primer Reverse Amplicon size
EEF1A1 $$**$7*77&*7&*7**&$$ *&*&77$777**&&7**$7* 113 bp
RPL13a &*7*&*7&7*$$*&&7$&$$ 7*7&$&7*&&7**7$&77&& 82 bp
VEGFĮ 77&&$**$*7$&&&7*$7*$*$7&*$* 7*$7&&*&$7$$7&7*&$7**7*$7*7 145 bp
ANG1 &77*7**&&&&7&&$$7&7$$ **&&&777*$$*7$*7*&&$ 94 bp
bFGF &&**7&$$**$$$7$&$&&$*7 7$7$*&777&7*&&&$**7&&7*7 94 bp
PDGF **$&7*&*77**7*$7*7$$ **$&$$*&$&&$&$777&&$* 141 bp
GDNF 7*$&77***7&7***&7$7*$$$& 7&*7$&*77*7&7&$*&7*&$7 87 bp
NGF 7&&$$*7&*&7*&&777*&$7$ $7$**&$7&&&$7&$*&&7&$77* 91 bp
NT3 *$$$&*&*$7*7$$**$$*&&$ **$&*7$**777***$7*7777*& 100 bp
BDNF &&$*$$$*77&**&&&$$7*$$*$ $**&7&&$$$**&$&77*$&7$ 91 bp
CNTF 7&&$$*7&*&7*&&777*&$7$ $7$**&$7&&&$7&$*&&7&$77* 91 bp
IL4 *&$*&7*$7&&*$77&&7*$$$ 77&&$$&*7$&7&7**77**&7 100 bp
IL5 $&&77**&$&7*&777&7$&7 &&&&77*&$&$*777*$&7& 148 bp
IL10 7$&**&*&7*7&$7&*$777 &$&7&$7**&777*7$*$7*&&77 111 bp
TSG-6 $*&$&**7&7**&$$$7$&$ $7&&$7&&$*&$*&$&$*$& 138 bp
https://doi.org/10.1371/journal.pone.0178011.t001
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Detection of DFX in MSC secretomes
Presence of DFX in the MSC secretomes was evaluated by High Performance Liquid Chroma-
tography (HPLC) based on a modified method reported by DeFrancia et al. [29]. A VWRHita-
chi LaChromElite chromatographic system equipped with autosampler, column oven adjusted
to 25˚C, and a UV-DAD detector adjusted to 430nm was used. In order to prevent metal inter-
ference, the entire system was previously purged with a 20mM EDTA solution (Sigma-
Aldrich). Deferoxamine was evaluated in samples of the MSC secretome before the washing
steps and after the first and second washing steps. For this, 50μl of each sample were first com-
plexed with 50μl of a 3mM ferric chloride solution (Sigma-Aldrich). Samples were incubated
for 5 minutes to obtain the ferroxamine form and 5μl of this solution were injected into the
chromatographic system with a mobile phase consisting of 15% methanol in an aqueous solu-
tion containing 0,5% triethylamine adjusted to pH 8.3. Samples were separated on a Kroma-
sil1 C18 column (4,6 x 100 mm) with 3.5μm particle size through a flow rate of 0.8ml/min.
Signals were quantified using a six point DFX standard calibration curve from 10μM to
2000μM (r2 0.998).
Isolation and culture of dorsal root ganglion (DGR) neurons
DRG neurons were harvested fromWistar rats at embryonic day 15 (E15). All procedures
were approved by the Institutional Animal Care and Use Committee of the School of Medical
Sciences, UNCuyo (Argentina).
Embryos at E15 were obtained from terminally anaesthetized (80mg/kg pentobarbitone i.p.)
pregnant rats. A total of 8 embryos from 2 litters were used in these experiments. E15 DRG neu-
rons were cultured following previously published protocols [30]. Briefly, DRGs from all levels
were dissected and enzymatically digested (0.25% trypsin in Ca2+ and Mg2+-free HBSS for 10
minutes followed by 0.25% collagenase for 10 minutes in standard DMEM at 37˚C). Enzymatic
reaction was stopped by addition of DMEM supplemented with 10% FBS. The ganglia were
then centrifuged for 3 minutes at 600 g, the supernatant discarded and the tissue resuspended
in DMEM/F12 (Gibco) supplemented with 10% FBS. The tissue was then mechanically dissoci-
ated and plated onto round coverslips (Bellco Glass, Germany), coated with 10ng/mm2 poly-
D-Lysine (Sigma-Aldrich) and 1ng/mm2 laminin (Sigma-Aldrich). Neurons were kept at 37˚C
and 5% CO2 in DMEM/F12 with 10% FBS. Cell density at plating was 2x10
5 neurons/ml. All
neurons were cultured in presence of 10ng/ml mouse NGF 7S (Alomone Labs, Israel). 24 hours
after plating, culture media was replaced with N2 medium (ThermoFisher, Waltham, MA) sup-
plemented with NGF 7S. Culture medium supplemented with NGF was replaced daily.
Incubation with MSC secretomes and apoptosis assay
Apoptosis was determined on DGR neurons on the 3rd day. For this, culture media were supple-
mented with: i) the secretome obtained form the preconditioning of 8x105 MSCs with 150μM
DFX; ii) the secretome obtained form the preconditioning of 8x105 MSCs with 400μMDFX; iii)
the secretome obtained form 8x105 non-preconditioned MSCs or iv) the vehicle. Culture medi-
um contains a basal 25mM glucose that is essential for DRG neuron culture. To produce a
hyperglycemic insult, 20mM additional glucose (yielding a total of 45mM glucose) was added to
the medium 4 hours after supplementation with the secretomes and maintained for 24 hours.
To determine the percentage of apoptotic cells, DRG neurons were fixed with 4% parafor-
maldehyde (Merck) and evaluated for apoptosis by the in situ TdT-mediated dUPT nick end
labeling (TUNEL) assay with an in situ cell death detection kit (Promega, Madison, WI) fol-
lowing manufacturer’s instructions. Cells were counterstained with 4’-6’-diamidino-2-pheny-
lindole (DAPI) (Invitrogen). Cells treated with DNAse I (Fermentas, Burlinton, Canada) were
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considered as positive controls. Cells treated with reaction solution but without terminal trans-
ferase were considered as negative controls. DRG neurons were examined using a Fluoview
FV10i confocal microscope (Olympus, Tokyo, Japan). More than 2500 DGR neurons were
examined for each condition. Data were analyzed with the Olympus FV10-ASW4.1 software.
Results were presented as percentages of apoptotic cells.
Statistical analysis
Data were presented as mean ± standart error of the mean (SEM). Multiple group comparisons
were performed by analysis of variance (ANOVA) followed by Bonferroni post hoc test, while
comparisons between two experimental groups were performed by Student’s t test. p<0.05
was considered statistically significant.
Results
Characterization of human AD-MSCs
Human AD-MSCs were isolated from subcutaneous adipose tissue samples obtained from
liposuction aspirates of four female patients undergoing cosmetic liposuction. Five days after
plating, MSCs demonstrated the characteristic long spindle-shaped morphology (Fig 1A), and
Fig 1. Characterization of human AD-MSCs. (A) Morphological characteristics of MSCs five days after plating. (B) Representative images of AD-MSCs at
passage three, differentiated towards adipogenic and osteogenic lineages. Lipids droplets were stained with Oil red-O whereas hydroxyapatite precipitates
were stained with alizarin red. (C) Flow cytometry analysis of AD-MSCs at passage three, for putative human MSC markers (CD29, CD13, CD105, CD73 and
CD90) and markers characteristic of other cell lineages (CD235a, CD31 and CD45). Grey histograms represent isotype controls while black histograms
represent specific antibodies. Data shown are representative of MSCs isolated from four different donors. Experiments were repeated three times at
technical level.
https://doi.org/10.1371/journal.pone.0178011.g001
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exhibited adipogenic and osteogenic differentiation when they were stimulated with the
appropriate differentiation media (Fig 1B). Additionally, cells at passage three were character-
ized according to the presence of putative human MSC surface markers and absence of surface
markers characteristic of other cell lineages. Flow cytometry analysis showed that AD-MSCs
were more than 98% positive for CD29, CD13, CD105, CD73, and CD90, and less than 1%
positive for CD235a, CD31 and CD45 (Fig 1C), indicating that the isolated cells had the typical
MSC phenotype.
Deferoxamine preconditioning increases HIF-1Į abundance without
affecting MSC morphology and survival
AD-MSCs were incubated with 150μM or 400μM of the hypoxic mimetic agent DFX or with
the vehicle (non-preconditioned cells). We chose these doses of DFX since it has been previ-
ously reported that, for others stem cells types, the incubation with this dose range improves
their therapeutic potential and has only a modest impact on stem cells survival [31, 32]. We
observed that 48 hours of preconditioning did not induce cell morphology changes (Fig 2A)
and did not significantly reduce cell survival (Fig 2B) (6.82x105 ± 0.20x105 cells after precondi-
tioning with 150μMDFX; 6.83x105 ± 0.22x105 cells after preconditioning with 400μMDFX
compared to 7.95x105 ± 0.43x105 cells in the non-preconditioned condition), suggesting that
48 hours of preconditioning with 150μM or 400μM of DFX have nontoxic effects on MSCs.
HIF-1ċ has been described as the main hypoxia marker. We observed that MSC precondition-
ing for 48 hours with DFX induced a dose-dependent increase in HIF-1ċ abundance (3.09 ± 0.60
folds of change for 150μMDFX preconditioned cells and 5.06 ± 1.86 folds of change for 400μM
DFX preconditioned cells, compared to 1 ± 0.16 folds of change for non-preconditioned cells)
(Fig 2C) supporting the hypoxic inductive effect of DFX.
Deferoxamine preconditioning increases the expression and secretion of
pro-angiogenic, neuroprotective and anti-inflammatory factors
It has been previously reported that high levels of HIF-1ċ, associated with hypoxic precondi-
tioning, induce the expression and secretion of high levels of pro-angiogenic factors including
VEGFċ [33]. However, we wanted to evaluate if DFX preconditioning of AD-MSCs could also
induce the expression and secretion of neuroprotective and anti-inflammatory factors relevant
for the clinical management of DN.
As expected, we observed that preconditioning of MSCs with 150μMDFX or 400μMDFX
induced a significant increase in the mRNA levels of the pro-angiogenic factors VEGFċ and
ANG-1, determined by RT-qPCR (Fig 3A) (for VEGFċ: 12.66 ± 4.42 folds of change for 150μM
DFX preconditioned cells and 13.01 ± 4.87 folds of change for 400μMDFX preconditioned cells,
compared to 1 ± 0.23 folds of change for non-preconditioned cells; for ANG-1: 4.24 ± 2.35 folds
of change for 150μMDFX preconditioned cells and 5.44 ± 2.18 folds of change for 400μMDFX
preconditioned cells, compared to 1 ± 0.21 folds of change for non-preconditioned cells). Impor-
tantly, these preconditioning also induced the expression of the neuroprotective factors GDNF,
NGF and NT3 (Fig 3B) (for GDNF: 5.08 ± 3.37 folds of change for 150μMDFX preconditioned
cells and 6.75 ± 2.62 folds of change for 400μMDFX preconditioned cells, compared to 1 ± 0.37
folds of change for non-preconditioned cells; for NGF: 2.56 ± 0.46 folds of change for 150μM
DFX preconditioned cells and 2.39 ± 0.54 folds of change for 400μMDFX preconditioned cells,
compared to 1 ± 0.06 folds of change for non-preconditioned cells; for NT3: 5.26 ± 1.33 folds of
change for 150μMDFX preconditioned cells and 5.82 ± 1.80 folds of change for 400μMDFX
preconditioned cells, compared to 1 ± 0.35 folds of change for non-preconditioned cells). We
also observed a significant increase in the expression of the anti-inflammatory factors IL4 and
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IL5 (Fig 3C) (for IL4: 5.55 ± 2.50 folds of change for 150μMDFX preconditioned cells and
7.43 ± 2.89 folds of change for 400μMDFX preconditioned cells, compared to 1 ± 0.20 folds of
change for non-preconditioned cells; for IL5: 26.17 ± 8.30 folds of change for 150μMDFX pre-
conditioned cells and 26.85 ± 8.53 folds of change for 400μMDFX preconditioned cells, com-
pared to 1 ± 0.30 folds of change for non-preconditioned cells). Increased expression of VEGF-
ċ, ANG-1, GDNF, NGF, NT3, IL4 and IL5 after DFX preconditioning seems to be specific for
the mentioned molecules, since this effect was not seen in other factors of the same families such
as bFGF and PDGF (pro-angiogenic molecules), BDNF and CNTF (neuroprotective molecules),
IL10 and TSG6 (anti-inflammatory molecules) (Fig 3A–3C).
Fig 2. Deferoxamine preconditioning increases HIF-1Į abundance without affecting MSC morphology and survival. (A) Morphological characteristics
of MSCs exposed to 150ȝM DFX, 400ȝM DFX or to the vehicle for 48 hours. (B) Quantification of MSC survival determined by trypan blue exclusion assay for
cells exposed to 150ȝM DFX, 400ȝM DFX or to the vehicle for 48 hours. Data is presented as number of living cells. (C) Quantification of HIF-1Į protein levels
in lysates of MSCs exposed to 150ȝM DFX, 400ȝM DFX or to the vehicle for 48 hours. Data were expressed as fold change in preconditioned versus non-
preconditioned cells. Quantitative data correspond to mean  SEM. N = 4 per experimental group (biological repeats). Experiments were repeated three times
at technical level. * p 0.05.
https://doi.org/10.1371/journal.pone.0178011.g002
MSC preconditioning increases the secretion of trophic factors relevant for DN treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0178011 May 19, 2017 9 / 22
Next, we evaluated whether the increase in the mRNA levels observed after DFX precondi-
tioning could also be correlated with an increase in the protein levels of these factors in the
MSC secretome. For this, we chose a representative factor of each family and measured its pro-
tein level in the MSC secretomes by ELISA. In accordance with our RT-PCR data, we observed
that preconditioning of MSCs by incubation with DFX (150μM or 400μM) induced a signifi-
cant increase in the protein levels of the pro-angiogenic factor VEGFċ and in the anti-inflam-
matory factor IL4 compared to the levels detected in the secretome of non-preconditioned
MSCs (Fig 4A and 4C) (for VEGFċ: 82.63 ± 22.77 ng/ml in the secretome of 150μMDFX pre-
conditioned cells and 100.8 ± 19.35 ng/ml in the secretome of 400μMDFX preconditioned
Fig 3. Deferoxamine preconditioning increases the expression levels of pro-angiogenic, neuroprotective and anti-inflammatory factors. Total
RNA was obtained from MSCs exposed to 150ȝM DFX, 400ȝM DFX or to the vehicle for 48 hours and subjected to quantitative reverse transcriptase–PCR
analysis. (A) Quantification of the mRNA levels of the pro-angiogenic factors VEGFĮ, ANG1, bFGF and PDGF. (B) Quantification of the mRNA levels of the
neuroprotective factors GDNF, NGF, NT3, BDNF and CNTF. (C) Quantification of the mRNA levels of the anti-inflammatory factors IL4, IL5, IL10 and TSG6.
Data of each target gene was normalized against the mRNA levels of the housekeeping genes EEF1A1 and RPL13A of the same sample and presented as
fold change of expression in preconditioned versus non-preconditioned cells. White bars represent non-preconditioned MSCs, gray bars represent MSCs
preconditioned with 150ȝM DFX and black bars represent MSCs preconditioned with 400ȝM DFX. Data is shown as mean  SEM. N = 4 per experimental
group (biological repeats). Experiments were repeated three times at technical level. * p 0.05.
https://doi.org/10.1371/journal.pone.0178011.g003
Fig 4. Deferoxamine preconditioning increases the secretion of pro-angiogenic, neuroprotective and anti-inflammatory factors. The secretomes
obtained from MSCs exposed to 150ȝM DFX, 400ȝM DFX or to the vehicle for 48 hours were concentrated 10 times (v/v) using 3 kDa cutoff filters and the
protein levels of selected factors were evaluated by ELISA. (A) Quantification of VEGFĮ in MSC secretomes. (B) Quantification of NGF in MSC secretomes.
(C) Quantification of IL4 in MSC secretomes. Data is presented as mean  SEM. N = 4 per experimental group (biological repeats). Experiments were
repeated three times at technical level. * p 0.05.
https://doi.org/10.1371/journal.pone.0178011.g004
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cells, compared to 8.75 ± 2.13 ng/ml in the secretome of non-preconditioned cells; for IL4:
1.96 ± 0.85 pg/ml in the secretome of 150μMDFX preconditioned cells and 4.33 ± 0.82 pg/ml
in the secretome of 400μMDFX preconditioned cells, compared to 0.42 ± 0.18 pg/ml in the
secretome of non-preconditioned cells). With regard to NGF and DFX, preconditioning
induced an increase in the protein level of this neuroprotective factor; however, it did not
reach statistical significance (Fig 4B) (409.5 ± 135.4 pg/ml in the secretome of 150μMDFX pre-
conditioned cells and 362.1 ± 104.1 pg/ml in the secretome of 400μMDFX preconditioned
cells, compared to 240.7 ± 34.8 pg/ml in the secretome of non-preconditioned cells).
Deferoxamine preconditioning increases the antioxidant capacity of
MSC secretomes
One of the regenerative mechanisms associated with the therapeutic effects of MSCs is the effi-
cient handling of high levels of oxidative stress [16]. It has been proposed that some of the anti-
oxidant molecules produced by MSCs could also be secreted [16, 34], reducing ROS levels in
the surrounding microenvironment. Therefore, we evaluated whether DFX preconditioning of
MSCs could increase the antioxidant capacity of the secretomes. The antioxidant system used
in this study includes enzymes such as superoxide dismutase, catalase and glutathione peroxi-
dase; macromolecules such as ferritin, and an array of small molecules including ascorbic acid,
ċ-tocopherol, Č-carotene, reduced glutathione, uric acid and bilirubin. Thus, the combined
antioxidant activities of all the constituents of the MSC secretomes were assessed. We observed
that DFX preconditioning significantly increased the antioxidant capacity of MSC secretomes
in a concentration-dependent manner (Fig 5) (5.1 ± 0.3 folds of change in the secretome of
150μMDFX preconditioned cells and 10.1 ± 1 folds of change in the secretome of 400μMDFX
preconditioned cells, compared to 1 ± 0.07 folds of change in the secretome of non-precondi-
tioned cells).
Deferoxamine is not present in the final secretomes obtained from
preconditioned MSCs
In order to use the MSC secretome as a therapeutic product, the preconditioning stimulus
must be completely eliminated after the preconditioning process. Due to the small size of
DFX, we aimed to eliminate this drug from the MSC secretomes subjecting them to two
sequential washing and re-concentration steps. By HPLC, we observed that DFX was present
in both (150μM and 400μMDFX) MSC secretomes before the washing steps, but its concen-
tration was reduced to very low levels (below quantification limits) after the second washing
step (Fig 6A and 6B).
The secretomes of DFX preconditioned MSCs reduce glucose-induced
DRG neuron death
Loss of DRG neurons has been described in vivo during DN [35] and in vitro after high-dose
glucose-induced injury [36, 37]. Therefore, the in vitro stimulation of DRG neurons with dia-
betes-inducer conditions would allow for the screening of neuroprotective compounds with
potential to prevent DN.
To evaluate the neuroprotective ability of the MSC secretomes, DRG neurons were pre-
treated with the secretomes of 150μMDFX preconditioned MSCs, the secretome of 400μM
DFX preconditioned MSCs, the secretome of non-preconditioned MSCs or the vehicle. The
dose for the secretomes was based on previous reports [38]. Four hours later, glucose level in
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culture media was raised from basal level (25mM glucose) to hyperglycemic level (45mM glu-
cose). Twenty-four hours later, DRG neurons were fixed and TUNEL-stained.
As previously described, hyperglycemic insult induced a significant increase in the rate of
apoptosis of DRG neurons (Fig 7A and 7B). (4.6 ± 0.6% in the 45mM glucose DRG neurons
compared to 1.8 ± 0.2% in the 25mM glucose DRG neurons). Pre-incubation of DRG neurons
with the secretome of non-preconditioned cells produced only a modest decrease in TUNEL
positive cells, while the pre-incubation with the secretome of 150μMDFX and 400μMDFX
preconditioned MSCs significantly decreased glucose-induced DRG neuron death (Fig 7A and
7B) (2.2 ± 0.5% in DRG neurons pre-treated with secretome from 150μMDFX preconditioned
MSCs; 1.6 ± 0.3% in DRG neurons pre-treated with secretome from 400μMDFX precondi-
tioned MSCs and 3.5 ± 0.4% in DRG neurons pre-treated with secretome from non-precondi-
tioned MSCs).
Discussion
Mesenchymal stem cells have emerged as a tool with great clinical potential. MSCs can be iso-
lated from a wide range of tissues [39, 40], of which bone marrow is the traditional and most
Fig 5. Deferoxamine preconditioning increases the antioxidant capacity of MSC secretomes. The
secretomes obtained from MSCs exposed to 150ȝM DFX, 400ȝM DFX or to the vehicle for 48 hours were
concentrated 10 times (v/v) using 3 kDa cutoff filters. Total antioxidant capacity was quantified on the
secretomes by colorimetric reactions. Data were expressed as fold change of total antioxidant activity in
preconditioned versus non-preconditioned MSC secretomes. Data correspond to mean  SEM. N = 4 per
experimental group (biological repeats). Experiments were repeated three times at technical level. * p 0.05.
https://doi.org/10.1371/journal.pone.0178011.g005
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frequently used source. However, bone marrow aspiration is invasive and is accompanied with
donor morbidity [41]. In contrast, adipose tissue is more accessible, can be obtained repeatedly
under local anesthesia with a minimum of patient discomfort and has a higher yield of MSCs
compared to that of bone marrow [42, 43]. Furthermore, AD-MSCs share many proprieties
with bone marrow MSCs. Thus, adipose tissue is nowadays the preferred source of MSCs for
regenerative therapy [42, 43]. Initially, it was postulated that the major mechanism associated
with the therapeutic effects observed after the administration of MSCs in animal models of dif-
ferent diseases was related to the ability of these cells to migrate to damaged tissues, differenti-
ate into the required cell type and replace dead cells [44]. However, it has been recently
observed that the number of transplanted cells that reach and functionally integrate into dam-
aged tissues is too low to account for their therapeutic effects [45]. Therefore, the generation of
a pro-regenerative microenvironment, through the paracrine secretion of trophic factors, is
Fig 6. Deferoxamine is not present in the final secretomes obtained from preconditioned MSCs. The secretomes
obtained from MSCs exposed to 150ȝM DFX or 400ȝM DFX for 48 hours were concentrated 10 times (v/v) using 3 kDa
cutoff filters. The concentrates were washed twice with 15ml of PBS and re-concentrated again with the same filters. (A)
Quantification by HPLC of DFX in the secretome of MSCs exposed to 400ȝM DFX before the washing steps and after
the first and second washing steps. (B) Quantification by HPLC of DFX in the secretome of MSCs exposed to 150ȝM
DFX before the washing steps and after the first and second washing steps. Quantitative data is presented as
mean  SEM. N = 4 per experimental condition (biological repeats). Experiments were repeated three times at technical
level. BQL: Below quantification limit.
https://doi.org/10.1371/journal.pone.0178011.g006
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now the most accepted therapeutic mechanism associated to MSCs. Thus, MSCs have been
described as the “injury drugstore” of the body [46]. This phenomenon is also observed after
local administration of MSCs in preclinical animal models of DN, in which it has not been pos-
sible to detect differentiation of MSCs into neurons, Schwann cells or endothelial cells despite
an evident recovery of motor and sensory nerve conduction velocity, recovery of the normal
structure of nerve fibers, and increased blood flow to damaged nerves [18, 19, 47]. These data
suggest that different trophic factors secreted by MSCs are responsible for reducing the symp-
toms characteristic of DN.
The broad spectrum of molecules secreted by MSCs is known as the secretome. In humans,
the MSCs secretome consists of over 100 biologically active molecules including different
types of cytokines, chemokines, and growth factors [48]. In different pathologies such as acute
myocardial infarction and brain or liver damage, it has been shown that the administration of
the MSC secretome is able to reproduce, at least in part, the therapeutic effect observed after
the administration of living cells [49, 50] while at the same time reducing the therapy complex-
ity and the cost. However, a major issue associated with the use of MSC secretome is that in
most cases the concentration of cytokines and growth factors are too low for therapeutic use
[51].
Recently, it has been reported that, due to the high plasticity of MSCs, it is possible to mod-
ify the MSC secretome baseline composition, by subjecting these cells to an in vitro precondi-
tioning stimulus, producing a biological product with a defined combination and ratio of
biomolecules specific for a determined pathology [23–25].
In this context, many different strategies are being developed in order to boost the para-
crine effect of MSCs, such as genetic engineering or pre-treatment with different physical or
chemical factors. For example, it has been reported that preconditioning of MSCs with hypoxia
Fig 7. The secretomes of DFX-preconditioned MSCs reduce glucose-induced DRG neuron death. DRG neurons
were pre-incubated with the secretomes of 150ȝM DFX-preconditioned MSCs, 400ȝM DFX-preconditioned MSCs or non-
preconditioned MSCs for 4 hours. Hyperglycemic insult was then induced increasing glucose levels to 45mM. (A)
Representative images of DRG neurons 24 hours after hyperglicemic insult. Green nuclei represent apoptotic TUNEL-
stained cells (marked by arrows). Nuclei were counterstained with DAPI (blue). (B) Quantification of percentage of TUNEL-
positive nuclei in each experimental condition. Quantitative data is presented as mean  SEM. N = 4 per experimental
condition.
https://doi.org/10.1371/journal.pone.0178011.g007
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(1%O2) stabilizes the HIF-1ċ protein and induces the secretion of high levels of pro-angio-
genic factors [52], while the preconditioning of MSCs with LPS or IFN-č induces the secretion
of molecules with anti-inflammatory activity [26, 27]. In this study, the iron chelator DFX was
used as a preconditioning stimulus because it acts as a hypoxic mimetic agent, interfering with
the degradation of HIF-1ċ [53]. We observed that the in vitro preconditioning of human
AD-MSCs for 48 hours with two concentrations of DFX did not affect MSCs viability. As
expected, these treatments induced the stabilization of HIF-1ċ, and led to the overexpression
of genes related to pro-angiogenic responses including VEGFċ and ANG-1. These results are
in agreement with earlier studies indicating that DFX can induce VEGFċ expression in various
cell types, such as pancreatic beta cells [54], endothelial cells [55], and bone marrow stromal
cells [33]. However, we also observed that the preconditioning of MSCs with DFX could also
increase the expression of potent neuroprotective factors including NGF, GDNF and NT-3,
and cytokines with anti-inflammatory activity such as IL4 and IL5. This enhancement in the
production of therapeutic molecules after DFX preconditioning was specific for the mentioned
factors, since this effect was not seen for other molecules of the same families e.g. bFGF,
PDGF, BDNF, IL10, and TSG6. Additionally, this study demonstrated that the up-regulation
of the mRNA levels of the mentioned factors correlates with an increased secretion of these
protective molecules. This data suggests that modulation of culture conditions by incubation
with DFX can be used to generate tailored MSCs, as well as to improve the MSC secretomes,
making them suitable for different therapeutic applications.
Finally, we observed that the secretome obtained after the preconditioning of MSCs with
DFX showed increased antioxidant capacity, enhancing its possible therapeutic use. These
results corroborate previous reports indicating that MSCs are able to secrete high levels of mol-
ecules with antioxidant activities and also antioxidant enzymes including superoxide dismut-
ase, catalase, and glutathione reductase [16, 34]. This study demonstrated that DFX
preconditioning could also modulate the antioxidant properties of MSCs.
The pathogenesis of diabetic neuropathy is multifactorial, involving both metabolic and
vascular components [3]. However, at the molecular level, the increase in ROS levels in mito-
chondria due to exacerbated glucose flux has been proposed as the central player in DN patho-
genesis [6, 7]. It has been reported that high intracellular ROS levels can induce DN
development acting on several levels. For example, neurons and Schwann cells are especially
sensitive to the damage induced by ROS, due to their high density of mitochondria, which
leads to cell apoptosis [7]. By secreting a broad range of neuroprotective factors (NGF, GDNF,
NT-3, BDNF and CNTF), Schwann cells play a central role in neuron survival but also in the
axonal regeneration of peripheral nerves after injury [56, 57]. Therefore, the early death of
these cells in DN induces a significant reduction of the local levels of neuroprotective factors
generating a vicious cycle that enhances nerve fiber degeneration and prevents their regenera-
tion [8]. Of special importance are the neurotrophins NGF and NT-3. These trophic factors
are clearly involved in growth, maintenance and survival of sympathetic and sensory neurons
[58, 59]. Additionally, increased ROS levels induce alterations in endothelial cells, generating
loss of the vasodilation capacity of epineural blood vessels and reduction in pro-angiogenic
factors production. This phenomenon leads to a reduction in the microcirculation of blood
vessels that irrigate nerve fibers and the induction of ischemia and neuronal dysfunction [60,
61].
Finally, increased oxidative stress also leads to the activation of the poly ADP-ribose poly-
merase (PARP) pathway, which is responsible for regulating pro-inflammatory cytokine
expression. This creates a chronic inflammatory state that exerts direct toxic effect on neurons
and Schwann cells. This process accelerates the demyelination and atrophy of the nerve fibers
and contributes to the chronic pain characteristic of DN patients [62].
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In diabetic rats, there is evidence of mitochondrial dysfunction and ROS accumulation in
DRG neurons, followed by induction of apoptosis [56, 63]. Additionally, it has been reported
that the in vitro incubation of DRG neurons with high glucose induces oxidative stress, caspase
cleavage and the ultrastructural hallmarks of apoptosis [37, 64]. Thus, DRG neurons are a
good model for the initial screening of potential drugs for the treatment of DN [37, 64].
Using this in vitromodel we observed that incubation of DRG neurons with the secretomes
of DFX preconditioned MSCs reduced their apoptotic rate after challenge with high glucose,
suggesting a therapeutic potential of the studied secretomes.
High prevalence of DN has driven the effort to develop different types of experimental ther-
apies guided to block the mechanisms involved in its progression. For example, oral or intrave-
nous administrations of antioxidants, mainly -lipoic acid, in different animal models of DN
produce an increase in nerve conduction velocity and a reduction in chronic pain [65, 66].
Additionally, the local administration of recombinant neuroprotective, pro-angiogenic, or
anti-inflammatory factors was correlated with a decreased apoptosis of neurons and Schwann
cells and with an increase in both motor and sensory nerve conduction velocity [67–72].
However, while most of these therapies have shown positive results in diabetic animals, the
transfer of these procedures to clinical studies has been very unsuccessful [73, 74] and none of
mentioned strategies are being routinely applied in clinical practice [75]. This seems to be
mainly related to the fact that DN pathogenesis is multifactorial and involves many interre-
lated mechanisms. Therefore, a single molecule-based therapy is unlikely to be effective.
A therapeutic approach simultaneously targeting the angiogenic, neurodegenerative,
inflammatory and oxidative processes, like the administration of the secretome of MSCs sub-
jected to a preconditioning stimulus with DFX, may have great value in DN treatment. Fur-
thermore, this treatment could be repeated over the time, since it does not generate an
immunological rejection [76].
Compared to the use of living stem cells, this type of product has several advantages includ-
ing: i) higher biosafety, since the administration of the MSC secretome has less bioethical con-
siderations, and fewer risks of tumor formation than the administration of living cells; ii)
immediate availability, since the MSC secretome can be lyophilized, favoring its storage, while
living cells require extensive time for expansion; iii) greater reproducibility of the therapeutic
effects, since biological variability of MSC secretomes can be minimized as it has a more
defined composition (which can for instance be determined by a proteomic approach) while
using MSCs may have more unpredictable effects; iv) easier handling, since biodrug adminis-
tration is easier, safer and requires less complex medical facilities than those necessary for the
administration of living cells: and v) lower production costs, since the MSC secretome can be
produced in large quantities, reutilizing the cells. Therefore, the use of the MSC secretome as a
therapy would reduce the high costs that are usually associated with the production of cell
therapies for which the cells must be obtained and expanded for each patient.
Compared with other preconditioning stimuli like cobalt chloride, DFX has the advantage
that it has been used in humans for more than three decades to treat iron overload diseases
[77]. Therefore, it is believed that the administration of this agent to humans is safe. This study
demonstrated that, even when used at high dose, DFX has no toxic effect on MSCs, which per-
mits fine adjustment of the preconditioning by varying the concentration of DFX. However,
one important feature for the clinical translation of this kind of biological therapy is that the
preconditioning stimulus can be completely removed from the final product. In this sense, we
have demonstrated that due to its small size, after two washing and re-concentration steps,
DFX concentration could be reduced to undetectable levels.
Further evaluation is needed to demonstrate whether the local administration of the secre-
tome of MSCs preconditioned with DFX could reverse the main functional and structural
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alterations characteristic of DN. Nevertheless, we believe that this strategy might also be useful
for the treatment of others neurodegenerative disorders including amyotrophic lateral sclero-
sis, Huntinton’s and Parkinson’s disease and traumatic brain injury, in which the presence of
neuroprotective, pro-angiogenic and anti-inflammatory factors are relevant [78]. We suggest
that the administration of the secretome of MSCs preconditioned with DFX in animal models
of these diseases could stimulate neural growth, decrease apoptosis, reduce levels of free radi-
cals, enhance angiogenesis and regulate inflammation, promoting the functional recovery of
the damaged organ.
Additionally, the preconditioning of MSCs with DFX could also be used prior to the admin-
istration of the cells to enhance their therapeutic effect. For example, it has been reported that
one of the main factors that limits the therapeutic efficacy of MSCs is the poor survival of
transplanted cells into the ischemic target tissue, which presents high levels of inflammatory
factors and free radicals generated by oxidative stress [79]. Recent studies involving overex-
pression of anti-oxidant, anti-apoptotic, or anti-inflammatory genes in MSCs have shown
improved survival after transplantation [80, 81]. Therefore, the preconditioning of MSCs with
DFX prior to their administration could also help to increase the tolerance of these cells to the
hypoxic microenvironment, enhancing their survival in the damaged tissues. Furthermore,
preconditioned MSCs may support the angiogenic process better than naïve MSCs because
they secrete more VEGF and enhance the proliferation and migration capacity of endothelial
cells [82].
Finally, experiments using autologous MSCs from diabetic patients have suggested that
these cells are less potent in their therapeutic potential, due to disease-induced cell dysfunc-
tion, limiting their clinical use [83, 84]. Still, the preconditioning we report here, with the over-
production of several trophic factors, could be a way to overcome these noxious defects.
Conclusions
Overexpression of survival molecules and growth factors appears to be a potent strategy to
enable MSC therapeutics. This paper described a preconditioning strategy that led to an
increase in the transcription and secretion of several potent pro-angiogenic, neuroprotective,
and anti-inflammatory factors. The secretomes of preconditioned MSCs had neuroprotective
effects when evaluated in an in vitromodel of DN.
This upregulation of various classes of biologically important factors may be one of the
greatest benefits of stem cell therapy compared to any single protein or gene therapy, enabling
a concerted effect of multiple neuro-angiogenic and anti-inflammatory cytokines necessary for
neurovascular recovery.
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